oxacillin has been researched along with ceftriaxone in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (63.16) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Brandsch, M; Luckner, P | 1 |
| Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Kwon, DH; Lu, CD | 1 |
| Jansen, WT; Milatovic, D; Verel, A; Verhoef, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Amsler, KM; Bush, K; Davies, TA; Jacobs, MR; Shang, W | 1 |
| Biek, D; Ge, Y; Sahm, DF; Talbot, GH | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Arhin, FF; Draghi, DC; Moeck, G; Parr, TR; Pillar, CM; Sahm, DF | 1 |
| Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR | 1 |
| Hiramatsu, K; Kuwahara-Arai, K; Sasaki, T; Tsubakishita, S | 1 |
| Anderson, KC; Kellogg, GE; Sarkar, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; Košmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Amada, H; Endo, M; Hitaka, K; Kamitani, M; Masuko, A; Mihara, Y; Mima, M; Ohtake, N; Sugiyama, H; Takata, I; Takeuchi, T; Tamura, Y; Tanaka-Yamamoto, N; Ushiyama, F; Wada, R | 1 |
| Bhando, T; Brown, ED; Carfrae, L; Ellis, MJ; Johnson, JW; MacNair, C; Magolan, J; Piquette, ZA; Ritchie, NE; Saliba, P | 1 |
1 review(s) available for oxacillin and ceftriaxone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for oxacillin and ceftriaxone
| Article | Year |
|---|---|
In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections.
Topics: Anti-Bacterial Agents; Cephalosporins; Enterobacteriaceae; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Skin Diseases, Bacterial; Staphylococcus | 2008 |
17 other study(ies) available for oxacillin and ceftriaxone
| Article | Year |
|---|---|
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
Topics: Animals; Anti-Bacterial Agents; beta-Lactams; Binding Sites; Caco-2 Cells; Dose-Response Relationship, Drug; Humans; Peptide Transporter 1; Protein Binding; Rats; Symporters | 2005 |
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Topics: Animals; beta-Lactams; Cell Line, Tumor; Dipeptides; Drug Design; Humans; Mammals; Models, Molecular; Oligopeptides; Peptide Transporter 1; Quantitative Structure-Activity Relationship; Substrate Specificity; Symporters | 2005 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Polyamine effects on antibiotic susceptibility in bacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactams; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Polyamines; Spermine; Staphylococcus aureus | 2007 |
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
Topics: Aminoglycosides; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Europe; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes; Vancomycin Resistance; Viridans Streptococci | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; United States | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Enterococcus faecium; Glycopeptides; Gram-Positive Bacteria; Humans; Lipoglycopeptides; Microbial Sensitivity Tests; Staphylococcus aureus; Streptococcus | 2009 |
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan | 2010 |
Origin and molecular evolution of the determinant of methicillin resistance in staphylococci.
Topics: Bacterial Proteins; Chromosomes, Bacterial; Evolution, Molecular; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Penicillin-Binding Proteins; Phylogeny; RNA, Ribosomal, 16S; Staphylococcus | 2010 |
Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
Topics: Anti-Bacterial Agents; beta-Lactams; Computational Biology; Drug Resistance, Bacterial; Hydrophobic and Hydrophilic Interactions; Ligands; Membrane Transport Proteins; Microbial Sensitivity Tests; Models, Molecular; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Regression Analysis; Thermodynamics | 2012 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
Lead optimization of 8-(methylamino)-2-oxo-1,2-dihydroquinolines as bacterial type II topoisomerase inhibitors.
Topics: Anti-Bacterial Agents; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Hep G2 Cells; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Quinolines; Streptococcus pneumoniae; Structure-Activity Relationship; Topoisomerase II Inhibitors; Transcriptional Regulator ERG; Vancomycin-Resistant Enterococci | 2020 |
Antibacterial Activity of Metergoline Analogues: Revisiting the Ergot Alkaloid Scaffold for Antibiotic Discovery.
Topics: | 2022 |